US contract research organization PPD has announced the opening of an office in Istanbul, Turkey, continuing the company's growth of its Phase II-IV clinical development services in eastern Europe. PPD will provide clinical monitoring services in key therapeutic areas from this location. The new office strengthens PPD's presence in eastern Europe beyond Russia and Ukraine, countries where the company is expanding through its pending acquisition of InnoPharm. Eastern Europe is an important, high-growth market for clinical trials and a region PPD has targeted for expansion, the firm says.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze